Acthar® GEL
(repository corticotropin injection) 80 U/mL

Acthar Gel Enrollment/Prescription Form
Please complete and email or fax toll-free
Phone: 888-435-2284
FAX: 877-937-2284
EMAIL: intake@supportandaccess.com

1 PATIENT & PRESCRIBER

PATIENT INFORMATION

Last Name:
First Name and Middle Initial:
Date of Birth:
Mobile Phone: Phone:
Preferred Language (other than English):

Address:
City:
State: Zip Code:
Email:
Caregiver:

Allergies: ☐ NKDA - No known drug allergies

Patient Sex: ☐ Male ☐ Female

(Additional space provided on pg 2)

INSURANCE INFORMATION

*Include a copy of the front and back of the patient's prescription benefit and insurance card(s) when submitting this form **OR** complete the fields to the right.*

Pharmacy Benefit Provider:
Subscriber #:
Group #:
Phone #:

Primary Medical Insurance:
Subscriber #:
Group #:
Phone #:

PRESCRIBER INFORMATION

HCP Name:
Specialty:
Address:
City: State: Zip Code:
State License Number:

NPI #: Tax ID #:
Office Contact Name:
Contact Phone: Extension:
Contact Fax:
Contact Email:

2 PRESCRIPTION: ACTHAR® GEL

SUBCUTANEOUS INJECTION

Preferred Specialty Pharmacy:

PLEASE ENROLL PATIENT IN ACTHAR PATIENT SUPPORT

ICD-10 Code (Required):

(SEE PG 2 FOR PRIMARY DIAGNOSIS CODES; FOR A MORE COMPLETE LIST, SEE APPENDIX A [NOT AN EXHAUSTIVE LIST])

Acthar Gel Single-Dose Pre-filled SelfJect™ Injector Subcutaneous Injection

☐ 80 Units/mL NDC 63004-8711-4 ☐ 40 Units/0.5 mL NDC 63004-8712-4

Frequency:

☐ Every 72 hours ☐ Every 48 hours ☐ Every 24 hours

Dispense quantity sufficient for up to 35 days

☐ Other:

Number of Refills:

OR

Acthar Gel 5 mL multi-dose vial (80 USP Units/mL): NDC 63004-8710-1 Subcutaneous Injection

☐ 80 Units ☐ 40 Units ☐ Other: Units

Frequency:

☐ Every 72 hours ☐ Every 48 hours ☐ Every 24 hours

Dispense quantity sufficient for up to 35 days

☐ Other:

Number of Refills:

VIAL SUPPLIES: Pharmacy to supply the following unless "OTHER" is specified

- Syringe: 1 ML
- Needle for Drawing: 20 G
- Needle for Injection: 25 G, 5/8"
- Sharps Container
- OTHER:

Pharmacy to dispense sufficient supplies to complete course of therapy. Pharmacist may elect to dispense alternate supplies as necessary.

OTHER INSTRUCTIONS: (Attach taper schedule and provide additional instructions, if applicable)

3 COMMERCIAL STARTER PROGRAM

The Acthar Gel Commercial Starter Program is available to eligible, commercially-insured patients while pursuing reimbursement. Terms and conditions apply. See actharhcp.com/csp-terms for full terms and conditions.

ICD-10 Code (Required):

Acthar Gel Single-Dose Pre-filled SelfJect™ Injector Subcutaneous Injection

☐ 80 Units/mL NDC 63004-8711-4 ☐ 40 Units/0.5 mL NDC 63004-8712-4

Frequency:

☐ Every 72 hours ☐ Every 48 hours ☐ Every 24 hours

☐ Other:

Number of Refills:

OR

Acthar Gel 5 mL multi-dose vial (80 USP Units/mL): NDC 63004-8710-1 Subcutaneous Injection

☐ 80 Units ☐ 40 Units ☐ Other: Units

Frequency:

☐ Every 72 hours ☐ Every 48 hours ☐ Every 24 hours

☐ Other:

Number of Refills:

VIAL SUPPLIES: Pharmacy to supply the following unless "OTHER" is specified

- Syringe: 1 ML
- Needle for Drawing: 20 G
- Needle for Injection: 25 G, 5/8"
- Sharps Container
- OTHER:

Pharmacy to dispense sufficient supplies to complete course of therapy. Pharmacist may elect to dispense alternate supplies as necessary.

OTHER INSTRUCTIONS: (Attach taper schedule and provide additional instructions, if applicable)

PRESCRIBER SIGNATURE: Please sign only ONE LINE below (by signing below you are agreeing to the Prescriber Consent section on page 4 of this document)

Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute

X
Dispense as Written Date

or

May Substitute / Product Selection Permitted / Substitution Permissible
There is no A/B rated substitute for Acthar. This space is required by certain states

X
Substitutions Allowed Date

Prescriber signature required for consent and to validate prescriptions. Prescriber attests that this is her/his signature. NO STAMPS. By signing, Prescriber certifies that the above is medically necessary.
ATTN: New York and Iowa providers, please submit electronic prescription. CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution."
For questions, please call: 1-888-435-2284 Monday through Friday (8:00 AM to 9:00 PM ET) Saturday (9:00 AM to 2:00 PM ET).

Acthar® GEL
(repository corticotropin injection) 80 U/mL

Acthar Gel Enrollment/Prescription Form
Please complete and email or fax toll-free
Phone: 888-435-2284
FAX: 877-937-2284
EMAIL: intake@supportandaccess.com

DIAGNOSIS AND MEDICAL INFORMATION

Patient Name:_____ **Date of Birth:**_____

DIAGNOSIS CODES: BELOW IS A LIST OF THE MOST COMMON CODES. A MORE COMPLETE LIST OF DIAGNOSIS CODES CAN BE FOUND IN APPENDIX A, PAGES 6 AND 7. THESE CODES HAVE BEEN PROVIDED FOR CONVENIENCE ONLY. THESE ARE NOT ALL POSSIBLE DIAGNOSIS CODES, AND NOT INTENDED TO INFLUENCE A DIAGNOSIS.

Please provide as much information as possible that corresponds with the patient's diagnosis (e.g., ICD-10 code, how Acthar is being prescribed for use, and organ involvement).

- ☐ ARTHROPATHIC PSORIASIS, UNSPECIFIED **L40.50**
- ☐ OTHER PSORIATIC ARTHROPATHY **L40.59**
- ☐ RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF MULTIPLE SITES WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.79**
- ☐ RHEUMATOID ARTHRITIS, UNSPECIFIED **M06.9**
- ☐ SYSTEMIC LUPUS ERYTHEMATOSUS, ORGAN OR SYSTEM INVOLVEMENT UNSPECIFIED **M32.10**
- ☐ GLOMERULAR DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS **M32.14**
- ☐ SYSTEMIC LUPUS ERYTHEMATOSUS, UNSPECIFIED **M32.9**
- ☐ OTHER DERMATOMYOSITIS WITH MYOPATHY **M33.12**
- ☐ POLYMYOSITIS, ORGAN INVOLVEMENT UNSPECIFIED **M33.20**
- ☐ POLYMYOSITIS WITH MYOPATHY **M33.22**
- ☐ SARCOIDOSIS **D86**
- ☐ OTHER DIAGNOSIS: _____

HOW ACTHAR IS PRESCRIBED FOR USE

If diagnosis is psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis, or ankylosing spondylitis, Acthar is being used as (select one below):

- ☐ Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation)
- ☐ Low-dose maintenance therapy (in selected cases)

If diagnosis is systemic lupus erythematosus or dermatomyositis/polymyositis, Acthar is being used (select one below):

- ☐ During an exacerbation Onset of exacerbation date: _____
- ☐ As maintenance therapy (in selected cases)

- ☐ Other: _____

ORGAN INVOLVEMENT

- ☐ Lungs
- ☐ Lymph nodes
- ☐ Skin and tissues
- ☐ Eyes
- ☐ Heart
- ☐ Brain and nervous system
- ☐ Bones, joints, cartilage, ligaments, tendons and muscles
- ☐ Spleen
- ☐ Liver
- ☐ Kidneys and urinary tract
- ☐ Salivary glands
- ☐ Sinuses
- ☐ Other: _____

HISTORY OF CORTICOSTEROID USE (if applicable). Please add details in the section below.

PLEASE CHECK ALL THAT APPLY:

A corticosteroid **was** tried with the following response(s):

- ☐ Corticosteroid use failed, but same response not expected with Acthar
- ☐ Patient hypersensitive or allergic to corticosteroids
- ☐ Patient intolerant of corticosteroids
- ☐ Other: _____

OR

A corticosteroid **was not** tried due to the following reason(s):

- ☐ Corticosteroid use is contraindicated for this patient
- ☐ Intravenous access is not possible for this patient
- ☐ Patient has known intolerance to corticosteroids
- ☐ Other: _____

CONCURRENT MEDICATIONS

RELEVANT TREATMENT HISTORY (Including recent corticosteroid history. Attach additional case notes as necessary.)

THERAPY NAME	DOSE	START DATE	STOP DATE (if applicable)	EXPLAIN OUTCOME WITH DETAIL (eg. type of outcome)

RELEVANT TREATMENT HISTORY (Including recent corticosteroid history. Attach additional case notes as necessary.)

ALLERGIES: ☐ NKDA - No known drug allergies _____

PRESCRIBER SIGNATURE: REQUIRED FOR DOCUMENTATION

I verify that the patient and Prescriber information on this enrollment form was completed by me or at my direction and that the information contained herein is complete and accurate to the best of my knowledge. I certify that my patient has agreed in writing to be contacted by Program administrators or UBC and be furnished with Program or other information or materials.

X _____
Signature

Acthar® GEL
(repository corticotropin injection) 80 U/mL

Acthar Gel Enrollment/Prescription Form
Please complete and email or fax toll-free
Phone: 888-435-2284
FAX: 877-937-2284
EMAIL: intake@supportandaccess.com

FOR COMPLETION BY PATIENT OR THEIR REPRESENTATIVE

Patient Name:_____ **Date of Birth:**_____

PATIENT AUTHORIZATION(S)

Patient Consent to allow Acthar Patient Support Team to work together with your insurance provider, pharmacy, advocacy organization and others to provide support on your behalf.

By signing this authorization, I authorize my physician(s), my health insurance company and my pharmacy providers (collectively, "Designated Parties") to use, disclose, and redisclose to Mallinckrodt ARD LLC ("Mallinckrodt"), the distributor of Acthar, and its agents, authorized designees and contractors, including Mallinckrodt reimbursement support personnel and United BioSource LLC ("UBC") or any other operator of Acthar Patient Support on behalf of Mallinckrodt (collectively, "Manufacturer Parties"), health information relating to my medical condition, treatment and insurance coverage (my "Health Information") in order for them to (1) provide certain services to me, including reimbursement and coverage support, patient assistance and access programs, medication shipment tracking, and home injection training, (2) provide me with support services and information associated with my Acthar therapy, (3) serve internal business purposes, such as marketing research, internal financial reporting and operational purposes, and (4) carry out the Manufacturer Parties' respective legal responsibilities.

Once my Health Information has been disclosed to Manufacturer Parties, I understand that it may be redisclosed by them and no longer protected by federal and state privacy laws. However, Manufacturer Parties agree to protect my Health Information by using and disclosing it only for the purposes detailed in this authorization or as permitted or required by law.

I understand that I may refuse to sign this authorization and that my physician and pharmacy will not condition my treatment on my agreement to sign this authorization form, and my health plan or health insurance company will not condition payment for my treatment, insurance enrollment or eligibility for insurance benefits on my agreement to sign this authorization form. I understand that my pharmacies and other Designated Parties may receive payment in connection with the disclosure of my Health Information as provided in this authorization. I understand that I am entitled to receive a copy of this authorization after I sign it.

I may revoke (withdraw) this authorization at any time by mailing a letter to Acthar Patient Support, 680 Century Point, Lake Mary, FL 32746. Revoking this authorization will end further disclosure of my Health Information to Manufacturer Parties by my pharmacy, physicians, and health insurance company when they receive a copy of the revocation, but it will not apply to information they have already disclosed to Manufacturer Parties based on this authorization. I also know I may cancel my enrollment in a patient support program at any time in writing by contacting Mallinckrodt via fax at 1-877-937-2284 or by calling Acthar Patient Support at 1-888-435-2284. This authorization is in effect for 5 years unless a shorter period is provided for by state law (MARYLAND HEALTHCARE PROVIDERS, under Maryland Code HG § 4-303(b)(4) this authorization expires ONE YEAR from the date of signature) or until the conclusion of any ongoing coverage support, whichever is longer, once I have signed it unless I cancel it before then.

THIS SECTION MUST BE COMPLETED IN ITS ENTIRETY, INCLUDING DATE

X_____

PATIENT NAME OR LEGAL REPRESENTATIVE	PATIENT OR LEGAL REPRESENTATIVE SIGNATURE	IF LEGAL REPRESENTATIVE, RELATIONSHIP TO PATIENT	DATE

Patient Consent to receive additional information from Mallinckrodt such as education on your disease and Acthar.

I authorize Mallinckrodt and its partners to use, disclose, and/or transfer the personal information I supply (1) to contact me and provide me with informational and marketing materials and clinical trial opportunities related to my condition or treatment by any means of communication, including but not limited to text, email, mail, or telephone; (2) to help Mallinckrodt improve, develop, and evaluate products, services, materials, and programs related to my condition or treatment; (3) to enroll me in and provide me with Acthar-related programs and services that I may select or refuse at any time; (4) to disclose my enrollment and use of these services to my prescriber and insurers; and (5) to use my information that cannot identify me for scientific and market research. This authorization will remain in effect until I cancel it, which I may do at any time in writing by contacting Mallinckrodt via fax at 1-877-937-2284 or by calling Acthar Patient Support at 1-888-435-2284. I may request a copy of this signed authorization.

THIS SECTION MUST BE COMPLETED IN ITS ENTIRETY, INCLUDING DATE

X_____

PATIENT NAME OR LEGAL REPRESENTATIVE	PATIENT OR LEGAL REPRESENTATIVE SIGNATURE	IF LEGAL REPRESENTATIVE, RELATIONSHIP TO PATIENT	DATE

Scan the QR Code below to save the Acthar Patient Support phone number to your mobile device's contacts (see steps below).

STEP 1
Open the camera on your mobile device

STEP 2
Hold your camera over the QR code to scan

STEP 3
Save your Acthar Patient Support Team information to your contacts

If patient is not present to sign the form, send them to
Acthar Consent.com
and have them sign electronically.

ACTHAR GEL COMMERCIAL STARTER PROGRAM TERMS & CONDITIONS: Eligible patients for this Program must meet the following criteria: have a valid prescription for a selected FDA-approved indication of systemic lupus erythematosus, dermatomyositis/polymyositis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or symptomatic sarcoidosis, have verified commercial or private insurance, and are not participating in Medicare, Medicaid, or any government-funded healthcare plan. This Program is valid for one shipment of Acthar Gel at a time as needed; however, the patient will no longer receive Acthar Gel under this Program when the patient receives insurance approval or a final denial of coverage. The patient agrees not to seek reimbursement from any third-party payer for all or any part of Acthar Gel dispensed pursuant to this Program. This Program is void where prohibited by law. Mallinckrodt reserves the right to rescind, revoke, or amend this Program at any time without notice. By participating in this Program, the patient agrees to these terms and conditions. Other terms and conditions apply. See actharhcp.com/csp-terms for full details.

Acthar® GEL
(repository corticotropin injection) 80 U/mL

Acthar Gel Enrollment/Prescription Form
Please complete and email or fax toll-free
Phone: 888-435-2284
FAX: 877-937-2284
EMAIL: intake@supportandaccess.com

RESOURCE PAGE. DO NOT NEED TO FAX BACK.

PRESCRIBER INSTRUCTIONS

1. **Complete pages 1 and 2 of the Acthar Enrollment/Prescription Form.**
2. **Have your patient read page 3, PATIENT AUTHORIZATION(S). Request that the patient sign both sections** to allow Acthar Patient Support to provide a complete level of support both during the approval process and after starting treatment. **Alternatively, direct the patient to provide this consent at ActharConsent.com.** Tell your patient to expect a call and save the Acthar Patient Support number, 1-888-435-2284.
3. **Email or fax pages 1, 2, and 3 of the completed Enrollment/Prescription Form** along with clinical notes, any medically relevant documentation, and copies of both the front and back of your patient's medical and prescription benefit card(s) **to intake@supportandaccess.com or 1-877-937-2284.**

Acthar Patient Support will process the Enrollment/Prescription Form and contact both you and your patient by phone, text, or email. Prior authorization assistance will only be provided for FDA-approved indications. Medicare, Medicaid, and other federal or state healthcare program patients may be ineligible for certain other aspects of Acthar assistance programs.

PRESCRIBER SIGNATURE ON PAGE 1 AUTHORIZES PRESCRIPTION, CONSENT, AND STATEMENT OF MEDICAL NECESSITY

By signing page 1, I certify that Acthar® Gel is medically necessary for this patient and that I have reviewed this therapy with the patient and will be monitoring the patient's treatment. I verify that the patient and Prescriber information on this enrollment form was completed by me or at my direction and that the information contained herein is complete and accurate to the best of my knowledge.

I understand that I must comply with my practicing state's specific prescription requirements, such as e-prescribing, state-specific prescription form, fax language, etc. Noncompliance with state-specific requirements could result in outreach to me by the dispensing pharmacy.

I authorize United BioSource LLC ("UBC"), the current operator of Acthar Patient Support, and other designated operators of the Program, to act on my behalf for the limited purposes of transmitting this prescription to and received by the designated Specialty Pharmacy by any means under applicable law, including via a designated third party or other operator of the Program.

I understand that representatives from the Program or UBC may contact me or my patient for additional information relating to this prescription. I acknowledge and agree that this prescription may be sent to and received by the designated Specialty Pharmacy by any means under applicable law, including via a designated third party or other operator of the Program, and that no additional confirmation of receipt of prescription is required by the designated Specialty Pharmacy.

I request that company-funded Acthar Injection Training Services be arranged for my patient. I understand that Acthar Injection Training Services are available for multiple visits but are NOT a home health nursing service and that I or my patient may opt out of any nursing services by notifying the Acthar Patient Support Team by calling 1-888-435-2284. Patients can contact their Nurse Navigator at any time about injection training.

PATIENT INSTRUCTIONS

Your Prescriber will submit the completed Acthar Enrollment/Prescription Form to Acthar Patient Support. After we receive the form, we will call you so we can help you get your medicine. Please be on the lookout and answer calls from 1-800, 1-888, or blocked numbers. If you have any questions, please call **1-888-435-2284** Monday through Friday from 8 AM to 9 PM ET or Saturday from 9 AM to 2 PM ET.

Acthar® GEL
(repository corticotropin injection) 80 U/mL

Acthar Gel Enrollment/Prescription Form
Please complete and email or fax toll-free
Phone: 888-435-2284
FAX: 877-937-2284
EMAIL: intake@supportandaccess.com

RESOURCE PAGE. DO NOT NEED TO FAX BACK.

IMPORTANT SAFETY INFORMATION

Contraindications

Acthar is contraindicated:

- For intravenous administration
- In infants under 2 years of age who have suspected congenital infections
- With concomitant administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of Acthar
- In patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin

Warnings and Precautions

- The adverse effects of Acthar are related primarily to its steroidogenic effects
- Acthar may increase susceptibility to new infection or reactivation of latent infections
- Suppression of the hypothalamic-pituitary-adrenal (HPA) axis may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA axis suppression after stopping treatment
- Cushing's syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
- Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Monitor blood pressure and sodium and potassium levels
- Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy
- Acthar can cause gastrointestinal (GI) bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain GI disorders. Monitor for signs of perforation and bleeding
- Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression to psychosis. Existing conditions may be aggravated
- Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis
- Prolonged use of Acthar may produce cataracts, glaucoma, and secondary ocular infections. Monitor for signs and symptoms
- Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Acthar activity
- There may be an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
- Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients
- Decrease in bone density may occur. Bone density should be monitored in patients on long-term therapy

Adverse Reactions

- Commonly reported postmarketing adverse reactions for Acthar include injection site reaction, asthenic conditions (including fatigue, malaise, asthenia, and lethargy), fluid retention (including peripheral swelling), insomnia, headache, and blood glucose increased
- The most common adverse reactions for the treatment of infantile spasms (IS) are increased risk of infections, convulsions, hypertension, irritability, and pyrexia. Some patients with IS progress to other forms of seizures; IS sometimes masks these seizures, which may become visible once the clinical spasms from IS resolve

Pregnancy

- Acthar may cause fetal harm when administered to a pregnant woman

Please see accompanying full Prescribing Information for additional Important Safety Information or visit https://www.actharhcp.com/Static/pdf/Acthar-PI.pdf

INDICATIONS AND USAGE

- Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus
- Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis)
- Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis
- Symptomatic sarcoidosis

Mallinckrodt Pharmaceuticals

APPENDIX A

RESOURCE PAGE. DO NOT NEED TO FAX BACK.

RHEUMATOLOGY

- ARTHROPATHIC PSORIASIS, UNSPECIFIED **L40.50**
- DISTAL INTERPHALANGEAL PSORIATIC ARTHROPATHY **L40.51**
- PSORIATIC ARTHRITIS MUTILANS **L40.52**
- PSORIATIC SPONDYLITIS **L40.53**
- PSORIATIC JUVENILE ARTHROPATHY **L40.54**
- OTHER PSORIATIC ARTHROPATHY **L40.59**
- STEVENS-JOHNSON SYNDROME **L51.1**
- STEVENS-JOHNSON SYNDROME-TOXIC EPIDERMAL NECROLYSIS OVERLAP SYNDROME **L51.3**
- OTHER ERYTHEMA MULTIFORME **L51.8**
- ERYTHEMA MULTIFORME, UNSPECIFIED **L51.9**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF UNSPECIFIED SITE **M05.40**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF RIGHT SHOULDER **M05.411**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF LEFT SHOULDER **M05.412**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF UNSPECIFIED SHOULDER **M05.419**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF RIGHT ELBOW **M05.421**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF LEFT ELBOW **M05.422**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF UNSPECIFIED ELBOW **M05.429**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF RIGHT WRIST **M05.431**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF LEFT WRIST **M05.432**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF UNSPECIFIED WRIST **M05.439**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF RIGHT HAND **M05.441**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF LEFT HAND **M05.442**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF UNSPECIFIED HAND **M05.449**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF RIGHT HIP **M05.451**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF LEFT HIP **M05.452**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF UNSPECIFIED HIP **M05.459**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF RIGHT KNEE **M05.461**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF LEFT KNEE **M05.462**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF UNSPECIFIED KNEE **M05.469**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF RIGHT ANKLE AND FOOT **M05.471**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF LEFT ANKLE AND FOOT **M05.472**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF UNSPECIFIED ANKLE AND FOOT **M05.479**
- RHEUMATOID MYOPATHY WITH RHEUMATOID ARTHRITIS OF MULTIPLE SITES **M05.49**
- RHEUMATOID ARTHRITIS OF UNSPECIFIED SITE WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.60**
- RHEUMATOID ARTHRITIS OF RIGHT SHOULDER WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.611**
- RHEUMATOID ARTHRITIS OF LEFT SHOULDER WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.612**
- RHEUMATOID ARTHRITIS OF UNSPECIFIED SHOULDER WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.619**
- RHEUMATOID ARTHRITIS OF RIGHT ELBOW WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.621**
- RHEUMATOID ARTHRITIS OF LEFT ELBOW WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.622**
- RHEUMATOID ARTHRITIS OF UNSPECIFIED ELBOW WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.629**
- RHEUMATOID ARTHRITIS OF RIGHT WRIST WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.631**
- RHEUMATOID ARTHRITIS OF LEFT WRIST WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.632**
- RHEUMATOID ARTHRITIS OF UNSPECIFIED WRIST WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.639**
- RHEUMATOID ARTHRITIS OF RIGHT HAND WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.641**
- RHEUMATOID ARTHRITIS OF LEFT HAND WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.642**
- RHEUMATOID ARTHRITIS OF UNSPECIFIED HAND WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.649**
- RHEUMATOID ARTHRITIS OF RIGHT HIP WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.651**
- RHEUMATOID ARTHRITIS OF LEFT HIP WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.652**
- RHEUMATOID ARTHRITIS OF UNSPECIFIED HIP WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.659**
- RHEUMATOID ARTHRITIS OF RIGHT KNEE WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.661**
- RHEUMATOID ARTHRITIS OF LEFT KNEE WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.662**
- RHEUMATOID ARTHRITIS OF UNSPECIFIED KNEE WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.669**
- RHEUMATOID ARTHRITIS OF RIGHT ANKLE AND FOOT WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.671**
- RHEUMATOID ARTHRITIS OF LEFT ANKLE AND FOOT WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.672**
- RHEUMATOID ARTHRITIS OF UNSPECIFIED ANKLE AND FOOT WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.679**
- RHEUMATOID ARTHRITIS OF MULTIPLE SITES WITH INVOLVEMENT OF OTHER ORGANS AND SYSTEMS **M05.69**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED SITE WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.70**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT SHOULDER WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.711**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT SHOULDER WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.712**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED SHOULDER WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.719**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT ELBOW WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.721**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT ELBOW WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.722**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED ELBOW WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.729**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT WRIST WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.731**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT WRIST WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.732**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED WRIST WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.739**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT HAND WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.741**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT HAND WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.742**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED HAND WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.749**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT HIP WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.751**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT HIP WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.752**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED HIP WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.759**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT KNEE WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.761**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT KNEE WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.762**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED KNEE WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.769**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT ANKLE AND FOOT WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.771**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT ANKLE AND FOOT WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.772**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED ANKLE AND FOOT WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.779**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF MULTIPLE SITES WITHOUT ORGAN OR SYSTEMS INVOLVEMENT **M05.79**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED SITE **M05.80**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT SHOULDER **M05.811**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT SHOULDER **M05.812**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED SHOULDER **M05.819**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT ELBOW **M05.821**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT ELBOW **M05.822**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED ELBOW **M05.829**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT WRIST **M05.831**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT WRIST **M05.832**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED WRIST **M05.839**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT HAND **M05.841**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT HAND **M05.842**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED HAND **M05.849**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT HIP **M05.851**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT HIP **M05.852**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED HIP **M05.859**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT KNEE **M05.861**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT KNEE **M05.862**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED KNEE **M05.869**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF RIGHT ANKLE AND FOOT **M05.871**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF LEFT ANKLE AND FOOT **M05.872**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF UNSPECIFIED ANKLE AND FOOT **M05.879**
- OTHER RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR OF MULTIPLE SITES **M05.89**
- RHEUMATOID ARTHRITIS WITH RHEUMATOID FACTOR, UNSPECIFIED **M05.9**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, UNSPECIFIED SITE **M06.00**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, RIGHT SHOULDER **M06.011**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, LEFT SHOULDER **M06.012**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, UNSPECIFIED SHOULDER **M06.019**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, RIGHT ELBOW **M06.021**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, LEFT ELBOW **M06.022**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, UNSPECIFIED ELBOW **M06.029**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, RIGHT WRIST **M06.031**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, LEFT WRIST **M06.032**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, UNSPECIFIED WRIST **M06.039**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, RIGHT HAND **M06.041**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, LEFT HAND **M06.042**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, UNSPECIFIED HAND **M06.049**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, RIGHT HIP **M06.051**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, LEFT HIP **M06.052**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, UNSPECIFIED HIP **M06.059**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, RIGHT KNEE **M06.061**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, LEFT KNEE **M06.062**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, UNSPECIFIED KNEE **M06.069**

APPENDIX A (Cont'd)

RESOURCE PAGE. DO NOT NEED TO FAX BACK.

RHEUMATOLOGY, ***continued***

- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, RIGHT ANKLE AND FOOT **M06.071**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, LEFT ANKLE AND FOOT **M06.072**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, UNSPECIFIED ANKLE AND FOOT **M06.079**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, VERTEBRAE **M06.08**
- RHEUMATOID ARTHRITIS WITHOUT RHEUMATOID FACTOR, MULTIPLE SITES **M06.09**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, UNSPECIFIED SITE **M06.80**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, RIGHT SHOULDER **M06.811**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, LEFT SHOULDER **M06.812**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, UNSPECIFIED SHOULDER **M06.819**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, RIGHT ELBOW **M06.821**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, LEFT ELBOW **M06.822**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, UNSPECIFIED ELBOW **M06.829**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, RIGHT WRIST **M06.831**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, LEFT WRIST **M06.832**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, UNSPECIFIED WRIST **M06.839**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, RIGHT HAND **M06.841**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, LEFT HAND **M06.842**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, UNSPECIFIED HAND **M06.849**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, RIGHT HIP **M06.851**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, LEFT HIP **M06.852**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, UNSPECIFIED HIP **M06.859**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, RIGHT KNEE **M06.861**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, LEFT KNEE **M06.862**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, UNSPECIFIED KNEE **M06.869**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, RIGHT ANKLE AND FOOT **M06.871**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, LEFT ANKLE AND FOOT **M06.872**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, UNSPECIFIED ANKLE AND FOOT **M06.879**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, VERTEBRAE **M06.88**
- OTHER SPECIFIED RHEUMATOID ARTHRITIS, MULTIPLE SITES **M06.89**
- RHEUMATOID ARTHRITIS, UNSPECIFIED **M06.9**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS OF UNSPECIFIED SITE **M08.00**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, RIGHT SHOULDER **M08.011**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, LEFT SHOULDER **M08.012**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED SHOULDER **M08.019**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, RIGHT ELBOW **M08.021**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, LEFT ELBOW **M08.022**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED ELBOW **M08.029**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, RIGHT WRIST **M08.031**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, LEFT WRIST **M08.032**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED WRIST **M08.039**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, RIGHT HAND **M08.041**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, LEFT HAND **M08.042**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED HAND **M08.049**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, RIGHT HIP **M08.051**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, LEFT HIP **M08.052**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED HIP **M08.059**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, RIGHT KNEE **M08.061**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, LEFT KNEE **M08.062**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED KNEE **M08.069**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, RIGHT ANKLE AND FOOT **M08.071**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, LEFT ANKLE AND FOOT **M08.072**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED ANKLE AND FOOT **M08.079**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, VERTEBRAE **M08.08**
- UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS, MULTIPLE SITES **M08.09**
- JUVENILE ANKYLOSING SPONDYLITIS **M08.1**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, UNSPECIFIED SITE **M08.20**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, RIGHT SHOULDER **M08.211**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, LEFT SHOULDER **M08.212**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, UNSPECIFIED SHOULDER **M08.219**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, RIGHT ELBOW **M08.221**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, LEFT ELBOW **M08.222**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, UNSPECIFIED ELBOW **M08.229**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, RIGHT WRIST **M08.231**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, LEFT WRIST **M08.232**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, UNSPECIFIED WRIST **M08.239**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, RIGHT HAND **M08.241**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, LEFT HAND **M08.242**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, UNSPECIFIED HAND **M08.249**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, RIGHT HIP **M08.251**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, LEFT HIP **M08.252**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, UNSPECIFIED HIP **M08.259**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, RIGHT KNEE **M08.261**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, LEFT KNEE **M08.262**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, UNSPECIFIED KNEE **M08.269**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, RIGHT ANKLE AND FOOT **M08.271**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, LEFT ANKLE AND FOOT **M08.272**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, UNSPECIFIED ANKLE AND FOOT **M08.279**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, VERTEBRAE **M08.28**
- JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET, MULTIPLE SITES **M08.29**
- JUVENILE RHEUMATOID POLYARTHRITIS (SERONEGATIVE) **M08.3**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED SITE **M08.40**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, RIGHT SHOULDER **M08.411**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, LEFT SHOULDER **M08.412**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED SHOULDER **M08.419**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, RIGHT ELBOW **M08.421**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, LEFT ELBOW **M08.422**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED ELBOW **M08.429**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, RIGHT WRIST **M08.431**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, LEFT WRIST **M08.432**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED WRIST **M08.439**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, RIGHT HAND **M08.441**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, LEFT HAND **M08.442**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED HAND **M08.449**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, RIGHT HIP **M08.451**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, LEFT HIP **M08.452**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED HIP **M08.459**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, RIGHT KNEE **M08.461**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, LEFT KNEE **M08.462**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED KNEE **M08.469**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, RIGHT ANKLE AND FOOT **M08.471**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, LEFT ANKLE AND FOOT **M08.472**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, UNSPECIFIED ANKLE AND FOOT **M08.479**
- PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, VERTEBRAE **M08.48**
- SYSTEMIC LUPUS ERYTHEMATOSUS, ORGAN OR SYSTEM INVOLVEMENT UNSPECIFIED **M32.10**
- ENDOCARDITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS **M32.11**
- PERICARDITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS **M32.12**
- LUNG INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS **M32.13**
- GLOMERULAR DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS **M32.14**
- TUBULO-INTERSTITIAL NEPHROPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS **M32.15**
- OTHER ORGAN OR SYSTEM INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS **M32.19**
- OTHER FORMS OF SYSTEMIC LUPUS ERYTHEMATOSUS **M32.8**
- SYSTEMIC LUPUS ERYTHEMATOSUS, UNSPECIFIED **M32.9**
- JUVENILE DERMATOMYOSITIS, ORGAN INVOLVEMENT UNSPECIFIED **M33.00**
- JUVENILE DERMATOMYOSITIS WITH RESPIRATORY INVOLVEMENT **M33.01**
- JUVENILE DERMATOMYOSITIS WITH MYOPATHY **M33.02**
- JUVENILE DERMATOMYOSITIS WITH OTHER ORGAN INVOLVEMENT **M33.09**
- OTHER DERMATOMYOSITIS, ORGAN INVOLVEMENT UNSPECIFIED **M33.10**
- OTHER DERMATOMYOSITIS WITH RESPIRATORY INVOLVEMENT **M33.11**
- OTHER DERMATOMYOSITIS WITH MYOPATHY **M33.12**
- OTHER DERMATOMYOSITIS WITHOUT MYOPATHY **M33.13**
- OTHER DERMATOMYOSITIS WITH OTHER ORGAN INVOLVEMENT **M33.19**
- POLYMYOSITIS, ORGAN INVOLVEMENT UNSPECIFIED **M33.20**
- POLYMYOSITIS WITH RESPIRATORY INVOLVEMENT **M33.21**
- POLYMYOSITIS WITH MYOPATHY **M33.22**
- POLYMYOSITIS WITH OTHER ORGAN INVOLVEMENT **M33.29**
- DERMATOPOLYMYOSITIS, UNSPECIFIED, ORGAN INVOLVEMENT UNSPECIFIED **M33.90**
- DERMATOPOLYMYOSITIS, UNSPECIFIED WITH RESPIRATORY INVOLVEMENT **M33.91**
- DERMATOPOLYMYOSITIS, UNSPECIFIED WITH MYOPATHY **M33.92**
- DERMATOPOLYMYOSITIS, UNSPECIFIED WITHOUT MYOPATHY **M33.93**
- DERMATOPOLYMYOSITIS, UNSPECIFIED WITH OTHER ORGAN INVOLVEMENT **M33.99**
- DERMATO(POLY) MYOSITIS IN NEOPLASTIC DISEASE **M36.0**
- ANKYLOSING SPONDYLITIS OF MULTIPLE SITES IN SPINE **M45.0**
- ANKYLOSING SPONDYLITIS OF OCCIPITO-ATLANTO-AXIAL REGION **M45.1**
- ANKYLOSING SPONDYLITIS OF CERVICAL REGION **M45.2**
- ANKYLOSING SPONDYLITIS OF CERVICOTHORACIC REGION **M45.3**
- ANKYLOSING SPONDYLITIS OF THORACIC REGION **M45.4**
- ANKYLOSING SPONDYLITIS OF THORACOLUMBAR REGION **M45.5**
- ANKYLOSING SPONDYLITIS OF LUMBAR REGION **M45.6**
- ANKYLOSING SPONDYLITIS OF LUMBOSACRAL REGION **M45.7**
- ANKYLOSING SPONDYLITIS SACRAL AND SACROCOCCYGEAL REGION **M45.8**
- ANKYLOSING SPONDYLITIS OF UNSPECIFIED SITES IN SPINE **M45.9**
- OTHER SERUM REACTION DUE TO OTHER SERUM, INITIAL ENCOUNTER **T80.69**
- SARCOIDOSIS **D86**